STOCK TITAN

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CANTON, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2021 financial results will be reported after the market closes on Tuesday, November 9th.

Management will host a conference call at 5:00 p.m. Eastern Time on November 9th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 3553677. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 3553677. The webcast will be archived at investors.organogenesis.com.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.


Organogenesis Holdings Inc

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Finance, Financial Conglomerates
US
Canton

About ORGO

headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.